Skip to search formSkip to main contentSkip to account menu

atamestane

Known as: 1-methyl-1,4-androstadiene-3,17-dione, Androsta-1,4-diene-3,17-dione, 1-methyl- 
A synthetic steroidal substance with antineoplastic activity. Atamestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

AndrostenedioneEnzyme Inhibitors

Narrower (1)

SH 489
analogs & derivativesatamestane/toremifene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model
SummaryWe compared the effects of atamestane (ATA) and toremifene (TOR) alone and in combination, with letrozole (LET) on bone… 
2007
2007
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
PURPOSE To compare time to progression (TTP) with a steroidal aromatase inhibitor (AI) atamestane (ATA) combined with toremifene… 
2006
2006
Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer.
LBA525 Background: This study addresses the principle of "complete estrogen blockade" by combining atamestane, an investigational… 
2005
2005
The effects of atamestane, toremifene, and atamestane plus toremifene compared to letrozole on bone, serum lipids and uterus
600 Background: Aromatase inhibitors (AI) and anti-estrogens combined may more completely eliminate oestrogenic signaling than… 
1999
1999
Aromatase inhibitors and enzyme stability.
The effects of two steroidal (4-hydroxyandrostenedione and atamestane) and three non-steroidal (fadrozole, vorozole, and… 
1998
1998
Inhibitors of aromatase prevent degradation of the enzyme in cultured human tumour cells.
The effects of two steroidal (4-hydroxyandrostenedione and atamestane) and three non-steroidal (fadrozole, vorozole and… 
1993
1993
Effects of estrogen deprivation on human benign prostatic hyperplasia
Review
1993
Review
1993
Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.
Benign prostatic hyperplasia (BPH) is the most common neoplastic growth in men and is the most frequent cause of urinary flow… 
Review
1991
Review
1991
Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
Atamestane is a new, competitive, and irreversible inhibitor of estrogen biosynthesis. Its pharmacologic action has been… 
Review
1991
Review
1991
Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
Today, human benign prostatic hyperplasia (BPH) is considered primarily to be a disease of the stroma, in which estrogens are… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)